Increase in Net Asset Value (NAV)
NAV increased by $252 million from the first quarter, driven primarily by a 38% increase in CVI share price and additional share purchases of $32 million.
Positive Developments in CVI
CVI paid down $90 million of its term loan due to improved crack spreads and enhanced cash flow profile.
Pharma Segment Progress
The initiation of VIVUS' pivotal trial for the pulmonary arterial hypertension asset, VI-0106, has been approved.
Strong Cash Position
Ended the quarter with $1.1 billion of cash and cash equivalents at the holding company, plus an additional $700 million of cash at the funds.
Caesars Digital Business Growth
Caesars Digital business grew revenue by 24% and EBITDA by 100% in the second quarter.